AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Origins === Modern dentistry in Chengdu developed in the early 20th century through the work of Western medical missionaries. Ashley Woodward Lindsay, a graduate of the Royal College of Dental Surgeons of Ontario in Toronto, left Canada for Chengdu in 1907. With assistance from physician and missionary Omar L. Kilborn, Lindsay established a dental clinic on Sishengci Street. A history published through China's National Health Commission describes the clinic as marking the beginning of modern dentistry in Chengdu. Sichuan University dates the institutional history of the present hospital to the establishment of the Renji Dental Clinic in 1907. It records the expansion of the clinic into the Renji Dental Hospital in 1912. The hospital describes the 1912 institution as China's first specialized dental hospital. West China Union University, a missionary-founded university established in Chengdu in 1910, subsequently became the principal institutional base for Lindsay's dental work. In 1917, the university established its dental education program. The dental school at West China Union University was the earliest dental education institution in China. Several early faculty members were trained at the University of Toronto Faculty of Dentistry, which credits these dentists with helping introduce a university-based model of dental education to China and with contributing to the development of national dental-education standards. In the late 1920s the medical and dental programs of West China Union University were brought into a combined academic structure.
=== Mass separation === The traditional IM-MS instrument uses a time‐of‐flight (TOF) mass spectrometer interfaced to an IMS. The TOF-MS has many advantages including the high speed of data acquisition and good sensitivity. Since mass spectral data is acquired on a microsecond time scale, multiple mass spectra are collected for each IMS spectrum (acquired on millisecond timescale). The quadrupole mass spectrometer has also been coupled to an IMS, although at a slower scan rate. Other mass spectrometers including the ion trap, Fourier transform ion cyclotron resonance (FT-ICR), or magnetic sector mass spectrometers have also been coupled with different IMS for various applications. Additionally, hybrid mass spectrometers have been interfaced to more than one ion mobility cell for tandem or IMSn–MSm applications.
== History == Methaqualone was first synthesized in India in 1951 by Indra Kishore Kacker and Syed Husain Zaheer, who were conducting research on finding new antimalarial medications. In 1962, methaqualone was patented in the United States by Wallace and Tiernan. By 1965, it was the most commonly prescribed sedative in Britain, where it has been sold legally under the names Malsed, Malsedin, and Renoval. In 1965, a methaqualone/antihistamine combination was sold as the sedative drug Mandrax in Europe, by Roussel Laboratories (now part of Sanofi S.A.). In 1972, it was the sixth-bestselling sedative in the US, where it was legal under the brand name Quaalude. Sold in the United States under the brand name Quaalude, methaqualone was moved to Schedule I in 1984 after prescription controls failed to curb diversion. Quaalude in the United States was originally manufactured in 1965 by the pharmaceutical firm William H. Rorer, Inc., based in Fort Washington, Pennsylvania. The drug name "Quaalude" is a portmanteau, combining the words "quiet interlude" and shared a stylistic reference to another drug marketed by the firm, Maalox. In 1978, Rorer sold the rights to manufacture Quaalude to the Lemmon Company of Sellersville, Pennsylvania. At that time, Rorer chairman John Eckman commented on Quaalude's bad reputation stemming from illegal manufacture and use of methaqualone, and illegal sale and use of legally prescribed Quaalude: "Quaalude accounted for less than 2% of our sales, but created 98% of our headaches." Both companies still regarded Quaalude as an excellent sleeping drug.
=== December === December 1 – COVID-19 pandemic: In California, the first case of Omicron variant, a highly mutated variant of COVID-19, is reported by the CDC in a San Francisco resident, who had traveled to South Africa. December 2 Major League Baseball begins a lockout of its players. It is their first lockout since 1990. COVID-19 pandemic: Minnesota reports their first case of Omicron variant. Two Georgia election officials, Ruby Freeman and Wandrea' ArShaye Moss, file a defamation lawsuit against The Gateway Pundit. The lawsuit is the first to be filed by individual election workers who were targeted during the 2020 presidential election. December 4 – Chris Cuomo is fired by CNN for his violations of journalistic ethics by aiding his scandal-ridden brother. December 9 Workers at a Starbucks in Buffalo, New York vote 19–8 to unionize, becoming the first Starbucks in the country to do so. A virtual summit, Summit for Democracy, was hosted by the United States "to renew democracy at home and confront autocracies abroad". December 10 – A late season tornado outbreak occurs in the Southern and Midwestern United States, causing major damage and killing at least 94 people. December 11 COVID-19 pandemic: North Carolina reports its first case of the Omicron variant in a student at UNC Charlotte. The MLS Cup 2021 hosted in Portland, Oregon, New York City FC defeated Portland Timbers after won 4–2 on penalties (Both teams drew 1–1 in regulation and extra time).
Sources: en.wikipedia.org
=== League === Serie B: Winners: 1946–47 (Group C), 1997–98 Serie C / Serie C1: Winners: 1937–38, 1965–66, 2007–08, 2014–15 Lega Pro Seconda Divisione: / Serie C2: Winners: 2012–13 Serie D: Winners: 2011–12 (as Salerno Calcio)
Acetylcysteine or N-acetylcysteine (NAC) is a mucolytic that is used to treat paracetamol (acetaminophen) overdose and to loosen thick mucus in individuals with chronic bronchopulmonary disorders, such as pneumonia and bronchitis. It has been used to treat lactobezoar in infants. It can be taken intravenously, orally (swallowed by mouth), or by inhalation by use of a nebulizer. It is also sometimes used as a dietary supplement. Common side effects include nausea and vomiting when taken orally. The skin may occasionally become red and itchy with any route of administration. A non-immune type of anaphylaxis may also occur. It appears to be safe in pregnancy. For paracetamol overdose, it works by increasing the level of glutathione, an antioxidant that can neutralize the toxic breakdown products of paracetamol. When inhaled, it acts as a mucolytic by decreasing the thickness of mucus. Acetylcysteine was initially patented in 1960 and came into medical use in 1968. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
In addition to Trinidad and Tobago, on 19 November, CNN described the Dominican Republic, El Salvador, Guyana, Panama, and Puerto Rico as supportive of the US military effort, and Argentina, Ecuador, and Paraguay as having "shown political support". The United Kingdom stated they provided logistical support to the US forces in apprehending a sanctioned vessel.
Sources: en.wikipedia.org
==== American Indian or Alaska Native ==== The obesity rate for American Indian or Alaska Native adults (over 30 BMI) in the US in 2015 was 42.9%. However, newer research based on waist circumference suggests that the actual rate of obesity among Native Americans is approximately 80%.
=== Direct liquid-introduction interface === The direct liquid-introduction (DLI) interface was developed in 1980. This interface was intended to solve the problem of evaporation of liquid inside the capillary inlet interface. In DLI, a small portion of the LC flow was forced through a small aperture or diaphragm (typically 10 μm in diameter) to form a liquid jet composed of small droplets that were subsequently dried in a desolvation chamber. The analytes were ionized using a solvent-assisted chemical ionization source, where the LC solvents acted as reagent gases. To use this interface, it was necessary to split the flow coming out of the LC column because only a small portion of the effluent (10 to 50 μl/min out of 1 ml/min) could be introduced into the source without raising the vacuum pressure of the MS system too high. Alternately, Henion at Cornell University had success with using micro-bore LC methods so that the entire (low) flow of the LC could be used. One of the main operational problems of the DLI interface was the frequent clogging of the diaphragm orifices. The DLI interface was used between 1982 and 1985 for the analysis of pesticides, corticosteroids, metabolites in horse urine, erythromycin, and vitamin B12. However, this interface was replaced by the thermospray interface, which removed the flow rate limitations and the issues with the clogging diaphragms. A related device was the particle beam interface (PBI), developed by Willoughby and Browner in 1984. Particle beam interfaces took over the wide applications of MBI for LC–MS in 1988.
The impact is heavy on editors, journalism and society, but we will never remain silent. Almost a thousand people work in the head office. We are far from ignoring their feelings of insecurity in their workplace. Our social rights and democracy are under unbearable pressure, and we must all fight together. From these attacks, we learned a lot of things, notably that we must always remain vigilant. Over the years, foreign media outlets also reported on the Moroccan mafia, particularly in Germany, Spain, Italy, Brazil, Colombia, Chile, Morocco, and the United Kingdom. BBC News stated in 2019 that the Netherlands was in the process of becoming a narco-state.
The closest relatives within the genus are Ambrosiella xylebori, the symbiont of Xylosandrus compactus (the black twig borer), and Ambrosiella grosmanniae, the symbiont of Xylosandrus germanus (the black stem borer). The genera of Ceratocystidaceae have been revised multiple times based on molecular data, incorporating sequences derived from other Ambrosiella species but not necessarily A. roeperi (and sometimes only including Ambrosiella that have now been moved elsewhere). These analyses imply the genus is most closely related to Huntiella. Within this taxon, studies incorporating the LSU rDNA of A. roeperi suggest that it, A. xylebori, A. hartigii, and A. beaveri comprise a monophyletic lineage excluding A. ferruginea (now Phialoporopsis ferruginea) and most closely aligned to Ceratocystis adiposa, subsequent analysis using 18S rDNA and translation elongation factor alpha confirms this and suggests a monophyletic clade of Ambrosiella associated with the scolytine tribe Xyleborini.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.